The most documented was immuno-adjuvant therapy with anti-PD-1, anti-CTLA-4, and anti-Tim-3 antibodies, which can reverse sepsis-induced immunosuppression and improve survival in sepsis (27, 32). The gene discussed is HAVCR2; the disease is Sepsis.